free evaluation

CONTACT US

1-888-567-2896
Email

Follow GENEX Disability

Subscribe to Our Blogs via E-mail

Your email:

Posts by category

The GENEX Social Security Disability Blog

Current Articles | RSS Feed RSS Feed

FY2013 Appropriations Bill: Continuing Disability Reviews

  
  
  
  
  

A Senate subcommittee approved a fiscal year 2013 bill that provides $158.8 billion in current year discretionary funding. Fiscal year 2013 runs from October 2012 through September 2013.

The bill provides funding for several activities that reduce fraud, waste, and abuse of Federal funding. Of particular significance is earmarked funding for improving fiscal accountability for Social Security programs.Benefits Terminated

Social Security Program Integrity.—The bill includes $1.024 billion, an increase of $268 million, for the Social Security Administration (SSA) to conduct continuing disability reviews and redeterminations of nonmedical eligibility under the Supplemental Security Income program. This investment will save approximately $8.1 billion over 10 years for the Social Security, Medicare, and Medicaid programs, a return on investment of $8 for every $1 spent.

While the subcommittee mark does not specifically suggest how much of the $1.024 billion will be targeted for the Continuing Disability Reviews (CDR) the agency has recognized a current backlog of over 1.5 million Continuing Disability Reviews.

Should the current subcommittee mark eventually result in a $1.024 appropriation, it is likely that a significant number of SSDI recipients will have reviews in FY2013. If benefit cessation is indicated by SSA, you have 15 days from the date of the notice to request benefit continuation should you elect to appeal the cessation determination. If you don’t request benefit continuation, your SSDI benefit will cease during an appeal.

If you need assistance with your continued entitlement to SSDI you may contact GENEX Social Security for a free consultation.

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics